Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Rubraca, rucaparib, Date of authorisation: 23/05/2018, Revision: 18, Status: Authorised

Call for expressions of interest for civil society representatives to participate in the work of EMA’s Paediatric Committee

Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Celdoxome pegylated liposomal, doxorubicin hydrochloride, Date of authorisation: 15/09/2022, Revision: 3, Status: Lapsed

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 6, Status: Authorised

PSUSA/00000843/202501

Medicines authorised during pandemic

Human medicines European public assessment report (EPAR): Eliquis, apixaban, Date of authorisation: 18/05/2011, Revision: 38, Status: Authorised

Paediatric investigation plans: Templates and forms